RxDoctor Payments Data

Krimish Bhagat, PA

Physician Assistant · Salem, NHNPI 1760001770

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 195 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 20 manufacturers reported payments, led by AbbVie at 34.3% of the total. 2025 is the largest year on record at $2,091, more than ten times the $121 reported in 2022. Among physician assistant clinicians in NH with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$3,884in general payments, 2019–2025

Across 195 payments — averaging $19.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • AstraZeneca$619
  • Lilly USA, LLC$332
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$237
  • Pfizer$171
  • Novo Nordisk$157
  • plus $1K from 14 others

What the payments were for

  • Food & beverage$3,884100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,884 in reported general payments places this provider in the 95th percentile of 782 physician assistant providers in New Hampshire.

See all physician assistant providers in New Hampshire

Medicare billing

Part B allowed, 2024
$137,781
Medicare patients
274
Services billed
2,452

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide46$59,251
EliquisApixaban45$58,259
OzempicSemaglutide28$46,166
Trelegy ElliptaFluticasone/Umeclidin/Vilanter27$37,783
XareltoRivaroxaban27$28,589
FarxigaDapagliflozin Propanediol23$24,485
JanuviaSitagliptin Phosphate11$10,841
Atorvastatin Calcium396$3,403
Colestipol Hcl18$2,406
Ezetimibe60$2,238
Metoprolol Succinate160$2,196
Lisinopril245$1,642
Rosuvastatin Calcium105$1,582
Omeprazole121$1,532
Gabapentin81$1,510

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$332$59,25146 claims
PfizerEliquis$171$58,25945 claims
Novo NordiskOzempic$157$46,16628 claims
GSKTrelegy Ellipta$145$37,78327 claims
AstraZenecaFarxiga$619$24,48523 claims
MerckJanuvia$66$10,84111 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 782 physician assistant providers in New Hampshire.

Other physician assistant in Salem

See the full list for New Hampshire

Where these figures come from

Is this you, or does something look wrong? →